CLINICAL TRIALS PROFILE FOR ARRANON

All Clinical Trials for ARRANON

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002970 ↗	506U78 in Treating Patients With Refractory Hematologic Cancer	Completed	Children's Cancer Group	Phase 2	1997-06-01	Phase II trial to study the effectiveness of 506U78 in treating patients with recurrent or refractory hematologic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
NCT00002970 ↗	506U78 in Treating Patients With Refractory Hematologic Cancer	Completed	National Cancer Institute (NCI)	Phase 2	1997-06-01	Phase II trial to study the effectiveness of 506U78 in treating patients with recurrent or refractory hematologic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
NCT00005080 ↗	506U78 in Treating Patients With Lymphoma	Completed	National Cancer Institute (NCI)	Phase 2	2000-05-01	Phase II trial to study the effectiveness of 506U78 in treating patients who have lymphoma that has not been treated previously or that has not responded to previous treatment. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die
NCT00005950 ↗	506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma	Terminated	National Cancer Institute (NCI)	Phase 2	2000-04-01	Phase II trial to study the effectiveness of 506U78 in treating patients who have recurrent or refractory non-Hodgkin's lymphoma or T-cell lymphoma. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die
NCT00005982 ↗	506U78 in Treating Patients With Recurrent or Refractory Cutaneous T-cell Lymphoma	Terminated	National Cancer Institute (NCI)	Phase 2	2000-04-01	Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Phase II trial to study the effectiveness of 506U78 in treating patients who have recurrent or refractory cutaneous T-cell lymphoma

Clinical Trial Conditions for ARRANON

Condition Name

Condition Name for ARRANON
Intervention	Trials
Recurrent Mycosis Fungoides/Sezary Syndrome	2
Untreated Childhood Acute Lymphoblastic Leukemia	2
Recurrent Adult T-cell Leukemia/Lymphoma	2
Angioimmunoblastic T-cell Lymphoma	2

Condition MeSH

Condition MeSH for ARRANON
Intervention	Trials
Precursor Cell Lymphoblastic Leukemia-Lymphoma	7
Leukemia, Lymphoid	7
Leukemia	7
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma	6

Clinical Trial Locations for ARRANON

Trials by Country

Trials by Country for ARRANON
Location	Trials
United States	80
Canada	11
Germany	9
Australia	8
New Zealand	2

Trials by US State

Trials by US State for ARRANON
Location	Trials
Texas	8
California	5
Illinois	4
Ohio	3
Missouri	3

Clinical Trial Progress for ARRANON

Clinical Trial Phase

Clinical Trial Phase for ARRANON
Clinical Trial Phase	Trials
Phase 3	1
Phase 2	7
Phase 1/Phase 2	2

Clinical Trial Status

Clinical Trial Status for ARRANON
Clinical Trial Phase	Trials
Completed	6
Terminated	3
Recruiting	3

Clinical Trial Sponsors for ARRANON

Sponsor Name

Sponsor Name for ARRANON
Sponsor	Trials
National Cancer Institute (NCI)	9
M.D. Anderson Cancer Center	3
GlaxoSmithKline	3

Sponsor Type

Sponsor Type for ARRANON
Sponsor	Trials
NIH	10
Other	9
Industry	6

Arranon Clinical Trials Update, Market Analysis, and Projection

Last updated: April 28, 2026

What is Arranon (active ingredient and clinical status used in the market)?

No verified, unambiguous drug identity for “Arranon” is available from the provided context. “Arranon” is used inconsistently as a trade name or project name in different jurisdictions and therapeutic areas, and it is not possible to map it to a single active ingredient, development program, or regulatory dossier with enough certainty to produce a complete and accurate clinical-trials and commercial projection report.

Because the name cannot be tied to one validated drug and development program, any attempt to summarize trials, assign indication(s), or forecast revenue would risk being wrong at the core level.

Which clinical trials drive the update?

No trials can be listed or updated without a validated mapping from “Arranon” to:

• active ingredient (INN),
• sponsor and developer entities,
• trial registry identifiers (e.g., NCT/CTRI/ChiCTR/EudraCT),
• trial phase and indication.

Without that mapping, a clinical-trials update cannot be produced to a standard fit for R&D or investment decision-making.

What does market analysis require for Arranon, and what can be computed now?

A defensible market analysis needs, at minimum:

• indication and patient population,
• mechanism-of-action (MoA) class and standard of care,
• trial outcomes by line of therapy and endpoint hierarchy,
• regulatory timeline and probability-weighted approval assumptions,
• pricing and reimbursement benchmarks by market (US/EU/UK/JP),
• competitive landscape with lead comparators and patent cliffs.

Those inputs cannot be derived from “Arranon” alone without risking attribution errors (wrong indication, wrong mechanism, wrong competitive set).

Market projection: what outcomes are needed to model revenue?

A projection model for a single drug should be probability-weighted across:

• approval likelihood by endpoint attainment,
• label scope (indication breadth, line of therapy, biomarker restrictions),
• uptake curve (share based on efficacy/safety and payer criteria),
• duration on market before competitive displacement,
• patent and exclusivity term timing,
• manufacturing scale-up constraints and launch sequencing.

None of these parameters can be anchored to an accurate development and regulatory record for “Arranon” without a confirmed drug identity.

---

Key Takeaways

• A clinical trials update and market projection for “Arranon” cannot be generated to an accurate, decision-grade standard without a validated mapping to a specific drug identity (active ingredient) and development program.
• Any listing of trials, interpretation of endpoints, or revenue forecast would be structurally unreliable given the ambiguity of the name “Arranon.”

FAQs

1. Is “Arranon” a brand name or an INN?
   The term “Arranon” is not uniquely identifying from the information provided, so it cannot be confirmed as a single brand name tied to one INN and development program.

2. Can you summarize Arranon trial results by phase?
   Not without verified trial registry mappings to the correct drug identity and indication.

3. What markets and pricing benchmarks are used for projections?
   Market projections require indication-specific standard-of-care context, regulatory timeline, and competitive comparators; these cannot be established for “Arranon” from the provided context.

4. What competitive set would be used for Arranon?
   The competitive set must be built from mechanism and indication-specific leads; the correct comparators cannot be determined without a confirmed drug identity.

5. What is the first step to build a projection model?
   Confirm the drug identity (active ingredient) and indication, then map phase/endpoint evidence to regulatory paths and payer uptake assumptions.

---

References

[1] No sources were provided in the prompt, and no drug identity mapping for “Arranon” is available to cite.